Head & neck cancer
Oncology· 2 reviewed drugs· 41787 cited findings behind them
What the regulatory reviews cover
Regulatory review documents in this library for Head & neck cancer include Keytruda and Opdivo. Keytruda was reviewed for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma, with an Objective Response Rate (pembrolizumab arm) of 74.4 and an Objective Response Rate (placebo arm) of 51.9. Opdivo was reviewed for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with an Overall Response Rate (ORR) of 31.7%.
It is important to note that different drugs were studied in different trials, and therefore, the figures presented are not head-to-head comparisons.
The drugs — one cited result each
| Keytruda Merck & Co., Inc. | Objective Response Rate (pembrolizumab arm): 74.4 Keytruda FDA Review, p.132 |
| Opdivo Bristol-Myers Squibb Company | Overall Response Rate (ORR): 31.7% BRISTOL MYERS SQUIBB — Opdivo FDA Summary Review (NDA/BLA 12, p.3 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.